Stockreport

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF 24- and 48-week MASH readouts, and it now plans a Phase 3 with a 52-week histology primary endpoint testing 1.8 mg (with 2.4 mg as an upside) as it moves into execution. [Read more]